Company intelligence / Profile preview
Nogra Pharma
Dublin, Irelandnographarma.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Nogra Pharma develops new therapeutic agents targeting immune-inflammatory-mediated diseases. Its pipeline includes small molecules, mRNA therapies, and ASOs. Lead programs have reached up to Phase III clinical trials in indications like Crohn’s disease and acneiform eruptions. The company partners extensively with academic institutions for early-stage research and with pharma/biotech companies for late-stage development and commercialization.
- Therapeutic areas
- GastroenterologyDermatologyImmunology
- Modalities
- small moleculesmRNAantisense oligonucleotides (ASO)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Torii Pharmaceutical Co., Ltd. (exclusive Japanese rights for Mongersen)Universities/research institutes globally
Beyond the preview
Go deeper on Nogra Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nogra Pharma.